Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer

NCT01240941 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Funding was not available

Conditions

Metastatic Breast Cancer

Interventions

DRUG: MK-2206
DRUG: Exemestane
DRUG: Goserelin

Sponsor

Vanderbilt-Ingram Cancer Center